Stock RENEURON GROUP PLC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Company ReNeuron Group Plc London S.E.

Equities

Biotechnology & Medical Research

Business Summary

ReNeuron Group plc is a United Kingdom-based Stem Cell and Exosome Technologies company that utilizes its stem cell technologies to develop treatments for disease with unmet needs. The Company has developed a proprietary stem cell-derived, exosome-based, drug delivery platform with customizable cellular targeting capabilities for the delivery of complex drug modalities. The Company’s CustomEX platform can be optimized for specific tissues targets and payloads leading to improvements in therapeutic outcome and a reduction in off-target effects. The Company offers a delivery mechanism for a variety of payloads such as small interfering Ribonucleic Acid (siRNA), messenger RNA (mRNA), proteins, small molecules and genes. Through its conditionally immortalized induced pluripotent stem cell (iPSC) platform, the Company has the ability to make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.

Sales per Business

GBP in Million2022Weight2023Weight Delta
Cell-based Therapies
100.0 %
0 100.0 % 1 100.0 % +31.51%

Sales per region

GBP in Million2022Weight2023Weight Delta
United Kingdom, United States, China and South East Asia
74.3 %
0 70.5 % 0 74.3 % +38.73%
United States
25.7 %
0 29.5 % 0 25.7 % +14.29%

Managers

Managers TitleAgeSince
John Hawkins DFI
 Director of Finance/CFO 58 14-09-30
Suzanne Hancock COO
 Chief Operating Officer - 16-12-31
Randolph Corteling CTO
 Chief Tech/Sci/R&D Officer - 22-03-02
Simon Dew PRN
 Corporate Officer/Principal - 22-10-31
Shaun Stapleton LAW
 General Counsel - 15-07-31

Members of the board

Members of the board TitleAgeSince
Martin Walton BRD
 Director/Board Member 61 22-03-21
Iain Ross CHM
 Chairman 71 21-06-30
Barbara Staehelin BRD
 Director/Board Member 61 21-07-13
Michael Owen BRD
 Director/Board Member 73 15-12-03
John Hawkins DFI
 Director of Finance/CFO 58 14-09-30

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 57,173,760 44,745,727 ( 78.26 %) 0 78.26 %

Shareholders

NameEquities%Valuation
Woodford Investment Management Ltd.
9.828 %
5,618,797 9.828 % 237 450 p
Hargreaves Lansdown Asset Management Ltd.
5.845 %
3,342,000 5.845 % 141 233 p
Schroder Investment Management Ltd.
4.962 %
2,837,100 4.962 % 119 896 p
KW Investment Management Ltd.
4.882 %
2,791,000 4.882 % 117 948 p
Obotritia Capital KGaA
4.609 %
2,635,000 4.609 % 111 355 p
IG Markets Ltd.
4.158 %
2,377,000 4.158 % 100 452 p
Rolf Elgeti
3.100 %
1,772,387 3.100 % 74 901 p
Richard Griffiths
2.989 %
1,708,662 2.989 % 72 208 p
Maven Capital Partners UK LLP
2.062 %
1,179,120 2.062 % 49 830 p
HSBC Bank Plc (Market-Maker)
1.221 %
698,000 1.221 % 29 497 p

Company contact information

ReNeuron Group Plc

Pencoed Business Park

CF35 5HY, Pencoed

+44 20 3819 8400

http://www.reneuron.com
address ReNeuron Group Plc

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Sales per region

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+4.09% 43.43B
LONZA GROUP AG Stock Lonza Group AG
+47.81% 41.69B
MODERNA, INC. Stock Moderna, Inc.
+9.45% 41.31B
CELLTRION, INC. Stock Celltrion, Inc.
-10.92% 27.14B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+9.32% 25.28B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-24.87% 18.47B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.70% 12.59B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
+1.28% 12.33B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+7.78% 11.03B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. RENE Stock
  4. Stock
  5. Company ReNeuron Group Plc